Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PITRESSIN TANNATE vs DESMODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone, ADH) that acts on V2 receptors in renal collecting ducts, increasing water reabsorption and reducing urine output. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor stimulation on endothelial cells.
Diabetes insipidus (central),Nocturnal enuresis (off-label),Variceal bleeding (off-label)
Central diabetes insipidus,Primary nocturnal enuresis,Hemophilia A with factor VIII levels >5%,von Willebrand disease (type I)
0.5-1 m L (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.
10 mg orally once daily
Terminal elimination half-life approximately 15 minutes (range 10–20 minutes). Clinically, due to rapid clearance, effects are short-lived; continuous infusion or depot formulations are required for sustained effect.
Terminal half-life: 8-12 hours; extended in renal impairment (up to 24 hours).
Metabolized primarily by the liver and kidneys via peptidases, with a half-life of about 10-20 minutes for vasopressin itself; the tannate formulation prolongs absorption.
Metabolized primarily by reduction of disulfide bonds; not extensively metabolized by CYP450 enzymes.
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal elimination negligible (<5%).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Negligible (<1%); mainly bound to plasma proteins primarily vasopressin-binding proteins and albumin, but binding is not clinically significant.
95%; primarily binds to albumin and alpha-1-acid glycoprotein.
Approximately 0.1 L/kg (range 0.08–0.12 L/kg). This low Vd indicates minimal tissue distribution, consistent with its predominant plasma volume confinement and renal clearance.
Vd: 0.5-0.7 L/kg; indicates moderate tissue distribution.
Intramuscular oil suspension: nearly 100% but with slow release. Subcutaneous: approximately 10–15% due to hydrolysis at injection site. Oral: negligible (<1%) due to enzymatic degradation.
Oral: 85-90% with food; 70-80% fasting.
Not significantly renally excreted; no specific dose adjustment recommended based on GFR.
No adjustment required for GFR ≥30 m L/min; contraindicated if GFR <30 m L/min
No specific guidelines; use with caution in hepatic impairment due to potential fluid imbalance.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 5 mg once daily; Child-Pugh C: contraindicated
0.1-0.3 m L (1-3 units) intramuscularly or subcutaneously, with dose adjusted based on response; monitor urine output and serum sodium.
Not recommended for use in pediatric patients
Start at lower end of dosing range (0.5 m L initially) due to increased risk of electrolyte disturbances and comorbid conditions; monitor serum sodium and fluid status closely.
Initiate at 5 mg once daily; monitor renal function closely
None.
No FDA black box warning.
Hyponatremia and water intoxication; cardiac effects including arrhythmias and ischemia; mesenteric ischemia; hypersensitivity reactions; use with caution in patients with coronary artery disease, hypertension, or renal impairment.
Risk of hyponatremia and seizures, especially in children and patients on fluid overload,Fluid restriction should be observed,Use with caution in patients with electrolyte imbalance, renal impairment, cystic fibrosis, or coronary artery disease,Avoid in patients with primary polydipsia
Hypersensitivity to vasopressin or components; anuria; chronic nephritis with nitrogen retention; cardiovascular disease (ischemic heart disease, advanced atherosclerosis, coronary thrombosis).
Hypersensitivity to desmopressin or any component,Moderate to severe renal impairment (Cr Cl <50 m L/min),Hyponatremia or history of hyponatremia,Primary polydipsia,Patients on diuretics or other drugs that increase risk of hyponatremia
Avoid excessive fluid intake beyond thirst to prevent water intoxication. Limit alcohol, which can inhibit vasopressin release and reduce drug efficacy. No specific food restrictions.
Avoid concurrent intake of large volumes of water or hypotonic fluids. Alcohol may reduce antidiuretic effect. Caffeine may increase urine output. Grapefruit juice may enhance absorption of oral formulations.
PITRESSIN TANNATE (vasopressin tannate) is classified as FDA Pregnancy Category C. In animal studies, vasopressin has been associated with decreased fetal weight and delayed ossification at high doses. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Vasopressin may cause uterine contractions and decrease placental perfusion, potentially leading to fetal hypoxia or distress, particularly in the third trimester.
Desmoda is contraindicated in pregnancy. First trimester: Risk of major congenital malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism. Second/Third trimester: Fetal growth restriction, oligohydramnios, premature closure of ductus arteriosus (if NSAID component).
It is unknown whether vasopressin is excreted in human breast milk. Due to its high molecular weight (tannate salt) and poor oral bioavailability, significant absorption by a nursing infant is unlikely. However, caution is advised. No M/P ratio is available.
Excreted in breast milk. M/P ratio not established. Avoid breastfeeding due to potential for serious adverse reactions (e.g., folate deficiency, kernicterus) in the infant.
No specific dose adjustments are established for pregnancy. However, because of increased plasma volume and renal clearance during pregnancy, lower serum concentrations may occur. Individualize dosing based on clinical response and avoidance of adverse effects such as hyponatremia and hypertension. Use the lowest effective dose.
Contraindicated in pregnancy. No dose adjustment recommended; avoid use. If accidental exposure occurs, discontinue immediately and initiate folate rescue therapy.
Pitressin Tannate is an aqueous suspension of vasopressin for intramuscular injection used for diabetes insipidus. Must be warmed and shaken vigorously before administration to ensure uniform suspension. Inject deeply IM into a large muscle; do not administer IV or subcutaneously. Onset is within 1-2 hours, duration 24-72 hours. Monitor for signs of water intoxication (headache, confusion, seizures) due to antidiuretic effect. Caution in coronary artery disease, hypertension, and renal impairment. Discontinue if abdominal cramps or nausea occur. Not for use in chronic nephrogenic diabetes insipidus.
Desmopressin is a synthetic analog of vasopressin used for central diabetes insipidus and nocturnal enuresis. Monitor serum sodium, especially in elderly or patients with fluid/electrolyte imbalance. Avoid in patients with hyponatremia or renal impairment. Tachyphylaxis may occur; dose adjustment may be needed. Intranasal route may be less reliable due to mucosal variability.
This medication is given as an injection into a muscle, usually every 1-3 days as prescribed.,Do not inject into a vein or under the skin; only into a muscle (buttock or thigh).,Warm the vial in your hands and shake it well just before use to mix the suspension evenly.,Drink only enough fluid to satisfy thirst; excessive fluid intake can lead to water intoxication.,Report any signs of water intoxication: severe headache, confusion, drowsiness, seizures, or difficulty breathing.,Avoid alcohol, which can interfere with the drug's effect and increase urine output.,Store the vial at room temperature away from light and do not freeze.,Monitor urine output and notify your doctor if it does not decrease or if side effects occur.
Take exactly as prescribed; do not exceed dose to avoid water intoxication.,Fluid restriction is critical: limit fluid intake for 1-2 hours after dosing, especially at night.,Report symptoms of hyponatremia: headache, nausea, vomiting, confusion, seizures.,For enuresis, take last dose at bedtime; avoid drinking 1 hour before and 8 hours after.,Intranasal formulations: administer alternately in each nostril; clear nasal passages before use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PITRESSIN TANNATE vs DESMODA, answered by our medical review team.
PITRESSIN TANNATE is a Antidiuretic Hormone Analog that works by Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.. DESMODA is a Antidiuretic Hormone Analog that works by Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone, ADH) that acts on V2 receptors in renal collecting ducts, increasing water reabsorption and reducing urine output. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor stimulation on endothelial cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PITRESSIN TANNATE and DESMODA depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PITRESSIN TANNATE is: 0.5-1 m L (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.. The standard adult dose of DESMODA is: 10 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PITRESSIN TANNATE and DESMODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PITRESSIN TANNATE is classified as Category C. PITRESSIN TANNATE (vasopressin tannate) is classified as FDA Pregnancy Category C. In animal studies, vasopressin has been associated with decreased fetal weight and delayed ossifi. DESMODA is classified as Category C. Desmoda is contraindicated in pregnancy. First trimester: Risk of major congenital malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism. Second/Th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.